Clinical Trial

Registry of Patients with Suspected Amyloidosis in Heart Failure

Study acronym: Regamic
Active, Not Recruiting
View on ClinicalTrials.gov →
Summary
Observational multicenter registry of cohorts with follow-up. Patients with heart failure, age ≥ 18 years, with clinical suspicion of cardiac amyloidosis and any LVEF value, treated in the field of Internal Medicine. Initially, a duration of two years was established to recruit at least 150 patients in the group with AC, and a follow-up of two years. Upon completion of the two years of follow-up, the continuity or completion of the registry will be assessed.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2021-12-14; most recent amendment 2024-09-30.
Status change: Recruiting → Active, Not Recruiting 2024-09-30
Status change: Not Yet Recruiting → Recruiting 2023-02-14
Trial Details
NCT Number NCT05176548
Lead Sponsor Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
Collaborators: Pfizer
Conditions Heart Failure
Enrollment 450 participants
Start Date 2022-01-15
Primary Completion 2024-03-31 (estimated)
Study Completion 2025-12-31 (estimated)
Updated on ClinicalTrials.gov 2024-10-01